Molecularly Targeted Therapies in Locally Advanced Non-Small-Cell Lung Cancer

被引：6

作者：

Devarakonda, Siddhartha ^{[1
]}

Morgensztern, Daniel ^{[2
]}

Govindan, Ramaswamy ^{[3
]}

机构：

[1] St Lukes Hosp, Dept Internal Med, Chesterfield, MO USA

[2] Yale Univ, Dept Med, New Haven, CT 06520 USA

[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

来源：

CLINICAL LUNG CANCER | 2013年 / 14卷 / 05期

关键词：

Concurrent chemoradiation; Locally advanced NSCLC; NSCLC; Targeted therapy; GROWTH-FACTOR-RECEPTOR; RANDOMIZED PHASE-III; INDUCTION CHEMOTHERAPY; THORACIC RADIOTHERAPY; MAINTENANCE GEFITINIB; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; CETUXIMAB; TRIAL; CHEMORADIOTHERAPY;

D O I：

10.1016/j.cllc.2013.03.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.

引用

页码：467 / 472

页数：6

共 50 条

[41] Gefitinib in a molecularly defined chemonaive population with advanced non-small-cell lung cancer
Teck, Lim Wan
Huat, Tan Bee
Ravindran, Kanesvaran
Balram, Chowbay
[J]. PHARMACOGENOMICS, 2008, 9 (10) : 1381 - 1382
[42] New and emerging targeted treatments in advanced non-small-cell lung cancer
Hirsch, Fred R.
Suda, Kenichi
Wiens, Jacinta
Bunn, Paul A., Jr.
[J]. LANCET, 2016, 388 (10048): : 1012 - 1024
[43] Advanced Non-Small-Cell Lung Cancer
Sohal, Sukhwinder S.
Walters, Eugene H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1998 - 1999
[44] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, Arjan
Wang, Yisong
Giaccone, Giuseppe
[J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
[45] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Arjan Gower
Yisong Wang
Giuseppe Giaccone
[J]. Journal of Molecular Medicine, 2014, 92 : 697 - 707
[46] Antiangiogenic therapies in non-small-cell lung cancer
Alshangiti, A.
Chandhoke, G.
Ellis, P. M.
[J]. CURRENT ONCOLOGY, 2018, 25 : S45 - S58
[47] Emerging therapies in non-small-cell lung cancer
Khuri, FR
Herbst, RS
Fossella, FV
[J]. ANNALS OF ONCOLOGY, 2001, 12 (06) : 739 - 744
[48] Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach
Hirsh, V.
[J]. CURRENT ONCOLOGY, 2010, 17 (02) : 68 - 78
[49] Targeted therapies in non small cell lung cancer
Giaccone, G.
[J]. EJC SUPPLEMENTS, 2005, 3 (02): : 38 - 38
[50] Targeted therapy for non-small-cell lung cancer
Belani, CP
[J]. LUNG CANCER, 2004, 45 : S7 - S7

← 1 2 3 4 5 →